New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
News|Articles|March 30, 2026
Q2 2026 preview: 4 FDA decisions to watch in pediatric care
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Yasmeen Qahwash
A review of 4 drugs to be discussed by the US FDA during Q2 2026, with links to coverage from MJH Life Sciences publications.
Advertisement
Advertisement
The second quarter of 2026 will include multiple advancements in pediatric care, including 4 drugs to be discussed by the FDA that will significantly advance disease management in this population. These include inhaled insulin (Afrezza), a rapid-acting inhaled human insulin for glycemic control, and teplizumab (Tzield), a disease-modifying intervention to delay the onset of type 1 diabetes.
Related to this article
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.
Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Advertisement
Advertisement